24/7 Patient Assistance: 760-405-8205

Deepa Jagadeesh, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. Deepa Jagadeesh is a medical oncologist from Cleveland, Ohio and she works at several hospitals in the area, such as Cleveland Clinic. She did her Medical Schooling from J.J.M. Medical College, Internship  from University of Massachusetts and Residency in Internal Medicine from University of Massachusetts. The doctor is certified in Medical Oncology , Internal Medicine & Hematology from American Board of Internal Medicine and has an experience of more than 20 years.


  • Education & Training

    dept_icon

    J.J.M. Medical College

    Medical School

    dept_icon

    University of Massachusetts

    Internship

    dept_icon

    University of Massachusetts

    Residency

    dept_icon

    University of Massachusetts

    Fellowship

  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Hematology

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    CLEVELAND CLINIC HOSPITAL

    Languages: English/Spanish

    (216) 445-0150

    9500 Euclid Ave Taussig Cancer Institute

    Cleveland, OH 44195

    Read More
  • Publications & Memberships

    Dr. Deepa Jagadeesh has contributed to 3 publications.

    GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

    Nazha A, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill BT, Kalaycio M, Liu H, Pohlman B, Sobecks R, Sekeres MA, Majhail NS; Bone Marrow Transplant.. 2016-12-01.

    See more >>

    Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.

    Jagadeesh D, Smith MR; Curr Treat Options Oncol. 2016-10-01.

    See more >>

    Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.

    Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman ...; Br. J. Haematol.. 2016-10-01.

    See more >>